Microrna Regulation and Human Protein Kinase Genes

Total Page:16

File Type:pdf, Size:1020Kb

Microrna Regulation and Human Protein Kinase Genes MICRORNA REGULATION AND HUMAN PROTEIN KINASE GENES REQUIRED FOR INFLUENZA VIRUS REPLICATION by LAUREN ELIZABETH ANDERSEN (Under the Direction of Ralph A. Tripp) ABSTRACT Human protein kinases (HPKs) have profound effects on cellular responses. To better understand the role of HPKs and the signaling networks that influence influenza replication, a siRNA screen of 720 HPKs was performed. From the screen, 17 “hit” HPKs (NPR2, MAP3K1, DYRK3, EPHA6, TPK1, PDK2, EXOSC10, NEK8, PLK4, SGK3, NEK3, PANK4, ITPKB, CDC2L5, CALM2, PKN3, and HK2) were validated as important for A/WSN/33 influenza virus replication, and 6 HPKs (CDC2L5, HK2, NEK3, PANK4, PLK4 and SGK3) identified as important for A/New Caledonia/20/99 influenza virus replication. Meta-analysis of the hit HPK genes identified important for influenza virus replication showed a level of overlap, most notably with the p53/DNA damage pathway. In addition, microRNAs (miRNAs) predicted to target the validated HPK genes were determined based on miRNA seed site predictions from computational analysis and then validated using a panel of miRNA agonists and antagonists. The results identify miRNA regulation of hit HPK genes identified, specifically miR-148a by targeting CDC2L5 and miR-181b by targeting SGK3, and suggest these miRNAs also have a role in regulating influenza virus replication. Together these data advance our understanding of miRNA regulation of genes critical for virus replication and are important for development novel influenza intervention strategies. INDEX WORDS: Influenza virus, host protein kinase, antiviral signaling, RNA interference, RNAi, short interfering RNA, siRNA, genome screen, microRNA, miRNA MICRORNA REGULATION AND HUMAN PROTEIN KINASE GENES REQUIRED FOR INFLUENZA VIRUS REPLICATION By LAUREN ELIZABETH ANDERSEN BS, Presbyterian College, 2005 A Dissertation Submitted to the Graduate Faculty of the University of Georgia in Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY ATHENS, GEORGIA 2011 © 2011 Lauren Elizabeth Andersen All Rights Reserved MICRORNA REGULATION AND HUMAN PROTEIN KINASE GENES REQUIRED FOR INFLUENZA VIRUS REPLICATION by LAUREN ELIZABETH ANDERSEN Major Professor: Ralph A. Tripp Committee: Robert J. Hogan S. Mark Tompkins Zhen Fu David Suarez Electronic Version Approved: Maureen Grasso Dean of the Graduate School The University of Georgia December 2011 iv DEDICATION To my sisters, Emily and Lindsey, for your unfailing love and encouragement. Thank you for making me smile is all your little ways. And to my Mom and Daddy, I love you. v ACKNOWLEDGEMENTS A thank you is extended to my advisors, Dr. Ralph A. Tripp and Dr. R Jeffrey Hogan, for their guidance, instruction and support through the years. I also extend my gratitude to the other members of my committee, Dr. S. Mark Tompkins, Dr. Zhen Fu, and Dr. David A. Suarez. Collectively this group made me into a better scientist, and for this, I am indebted. I thank those who have helped me over the years, particularly Dr. Abhijeet Bakre for his continuous mentorship, extensive knowledge and encouragement. I am also grateful to current and past members of the Animal Health Research Center, especially Frank (Tank) Michel, Stephanie Gavrielides, Jamie Barber, Jackelyn Crabtree, Cheryl Jones, and Keegan Coleman. A special thank you is extended to Alaina Mooney, for her devoted friendship and intelligent conversation. I also thank the Center of Excellence for Influenza Research and Surveillance, the Georgia Research Alliance, Dharmacon ThermoFisher, the RNAi Global Consortium and The Graduate School of The University of Georgia for providing support for my training. Finally, I thank my family for their unfailing patience and support throughout my experience as a Ph.D. student. vi TABLE OF CONTENTS Page ACKNOWLEDGEMENTS ..................................................................................... v LIST OF TABLES ................................................................................................. ix LIST OF FIGURES ............................................................................................... x CHAPTER 1 INTRODUCTION .................................................................................. 1 2 LITERATURE REVIEW ........................................................................ 5 Overview of Influenza Virus ........................................................... 5 Influenza Virus Replication .............................................................. 7 Pathogenesis of Influenza Virus and the Host Response ............. 11 Disease Intervention ..................................................................... 17 RNA Interference (RNAi) ............................................................... 19 microRNA (miRNA) Regulation in the Host Response .................. 20 RNAi and the Genome .................................................................. 22 siRNA Genome High-Throughput Screens (HTS) ......................... 24 Host Signaling Pathways important for Influenza Virus Replication… ................................................................................. 29 miRNA Regulation of Host Cell Signaling ..................................... 34 miRNA Expression During Viral Infection ...................................... 38 Next Generation Antivirals ............................................................ 41 vii References .................................................................................... 42 3 USING A RNAI GENOME SCREEN TO IDENTIFY HUMAN PROTEIN KINASE GENES REQUIRED FOR INFLUENZA A REPLICATION IN HUMAN ALVEOLAR EPITHELIAL CELLS ......................................... 71 Introduction ................................................................................... 73 siGENOME Assay ......................................................................... 76 Cell Lines and Susceptibility to Infection ....................................... 77 siRNA Controls and Transfection Conditions ................................ 78 Infection Assay .............................................................................. 80 Validation by Proof-of-Concept ..................................................... 81 Screen Results .............................................................................. 81 Normalization, Z-score Analysis and hot Identification .................. 82 Conclusions .................................................................................. 83 References .................................................................................... 92 4 MICRORNA REGULATION OF HUMAN PROTEIN KINASE GENES REQUIRED FOR INFLUENZA VIRUS REPLICATION ...................... 98 Abstract ......................................................................................... 99 Introduction ................................................................................. 101 Materials and Methods ................................................................ 104 Results ........................................................................................ 113 Discussion ................................................................................... 120 Acknowledgements ..................................................................... 129 References .................................................................................. 140 viii 5 HOST GENE TARGETS FOR NOVEL INFLUENZA THERAPIES ELUCIDATED BY HIGH-THROUGHPUT RNA INTERFERENCE SCREENS ........................................................................................ 152 Introduction ................................................................................. 153 The RNAi Pathway ...................................................................... 155 General workflow of host-pathogen screening using RNAi technology ................................................................................... 156 siRNAs and SHRNAs .................................................................. 159 miRNAs ....................................................................................... 162 Cell Types ................................................................................... 163 Viruses ........................................................................................ 164 Meta-analysis of RNAi screens for influenza virus ...................... 166 Challenges of RNAi Screening .................................................... 171 Comparing RNAi screening to analogous technologies .............. 173 Concluding Remarks ................................................................... 176 References .................................................................................. 182 6 CONCLUSIONS ............................................................................... 197 APPENDICES A SUPPLEMENTAL DATA .................................................................. 200 ix LIST OF TABLES Page Table 4.1 Human kinase genes identified important for influenza virus replication in primary screen ............................................................................... 139 Table 4.2 Host cells pathways predicted for validated genes ........................... 140 Table 5.1 Comparison of the screen stages for shRNA and siRNA screens .... 183 Table 5.2 Comparison of genome screens for influenza virus .......................... 182 Table S1. Dharmacon siRNA Sequences ......................................................... 206 Table S2. Normalized primary screen scores,
Recommended publications
  • Wo 2010/075007 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075007 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) G06F 19/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/067757 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 11 December 2009 ( 11.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 12/3 16,877 16 December 2008 (16.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): DODDS, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, W., Jean [US/US]; 938 Stanford Street, Santa Monica, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, CA 90403 (US).
    [Show full text]
  • ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn Product datasheet for AP08962PU-N ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: ELISA, IHC, WB Recommended Dilution: ELISA: 1/32000. Immunohistochemistry on Paraffin Sections: 3.75 µg/ml. Western Blot: 1 - 3 µg/ml. Reactivity: Canine, Human Host: Goat Clonality: Polyclonal Immunogen: Synthetic peptide from C-terminus of human ALS2CR2 Specificity: This antibody reacts to STE20-Related Kinase Adaptor Beta (STRADB/ALS2CR2) at aa 406-418. It is expected to recognise both human isoforms: ILPIP-alpha (NP_061041.2) and ILPIP-beta (AAF71042.1). Formulation: Tris saline buffer, pH 7.3, 0.5% BSA, 0.02% sodium azide State: Aff - Purified State: Liquid purified Ig Concentration: lot specific Purification: Immunoaffinity Chromatography Conjugation: Unconjugated Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. Database Link: Entrez Gene 55437 Human Q9C0K7 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 ALS2CR2 (STRADB) 406-418) Goat Polyclonal Antibody – AP08962PU-N Background: Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2, is connected to transferase/kinase activity and ATP binding, it has recently been shown to interact with XIAP, a member of the IAP (Inhibitor of Apoptosis) protein family.
    [Show full text]
  • Robert Miller CTN, Matthew Miller Nutrigenetic Research Institute, Ephrata, PA, United States
    Increased Genetic Variants Found in Acetylation & Lipid Synthesis Genes in Chronic Lyme Disease Patients (Phase V) Robert Miller CTN, Matthew Miller NutriGenetic Research Institute, Ephrata, PA, United States Some patients with Lyme disease do not respond well to treatment: it has been hypothesized this may be due to difficulty with detoxification and inflammation. Xenobiotics such as plastics, industrial chemicals, drugs, pesticides, fragrances, and environmental pollutants need to be detoxified by the body [1]. Phase I CYP450 enzymes and Phase II conjugation pathways are needed to eliminate these toxins through the urine, bile, and stool [2]. The balance between protein acetylation and deacetylation plays a critical role in the regulation of gene expression, signaling pathways, and affects a large range of cellular processes, many related to detoxification. Acetylation is the Phase II Conjugation Reaction process of introducing an acetyl functional group (acetyl-CoA) onto a chemical compound by N-Acetyltransferase (NAT). Acetylation can alter gene expression epigenetically. Acetylation is an important route of metabolism for xenobiotics [3]. Deacetylation is the removal of an acetyl group. For proper acetylation, there needs to be an adequate supply of acetyl-CoA. The PANK genes are responsible for catalyzing the ATP- dependent phosphorylation of pantothenate (vitamin B5) to create 4′-phosphopantothenate, which is needed to create adequate Acetyl- CoA [4]. The NAT enzymes are responsible for carrying out acetylation of the xenobiotics [5]. Acetyl-CoA is also needed for the expression of Nrf2 and ARE (Antioxidant Response Element), which make glutathione for the conjugation of xenobiotics [6]. The ACAT2 gene is an enzyme involved in lipid metabolism, which results in the creation of hormones, DHEA, and cortisol [7].
    [Show full text]
  • Signaling in the Type I Interferon Antiviral Innate Immune Response
    Signaling in the type I interferon antiviral innate Most vertebrate cells respond to viral infection by producing and sensing NF-κB, transcription factors that trigger the expression of genes encod- immune response type I interferon (IFN), which establishes an antiviral state characterized ing type I IFN proteins and other mediators of innate immune activation. by inhibition of viral replication, apoptosis of infected cells, and stimu- Type I IFN proteins bind to the type I IFN receptor and activate Janus ki- David E Levy & Isabelle J Marié lation of innate immune mechanisms that augment subsequent adaptive nase–signal transducer and activator of transcription (Jak-STAT) signaling 4,2 immune responses. Vertebrate cells detect virus infection either via the and formation of the trimeric transcription factor complex ISGF3, which #$ cytoplasmic RNA helicase sensors RIG-I and MDA-5, the cytoplasmic promotes expression of antiviral effector proteins as well as proteins that -$ DNA-dependent activator of IFN-regulatory factor (DAI), and/or via a positively and negatively modulate subsequent signaling. This poster high- pathway initiated by transmembrane Toll-like receptors (TLRs). All path- lights common and distinct components of these pathways that together ways culminate in activation of interferon regulatory factor (IRF) and lead to a highly orchestrated innate immune response to viral infection. 42!- -!, 42)& -Y$ Pathogen recognition: the cytosolic pathway and TYK2 kinases, respectively. IFN binding results in kinase Many viruses replicate in the cell cytoplasm after invading cells activation, receptor phosphorylation, and STAT protein recruit- )2!+ 2)0 by fusion either with the plasma membrane or with endosomal ment and tyrosine phosphorylation.
    [Show full text]
  • Androgen Receptor Binding Sites Identified by a GREF GATA Model
    doi:10.1016/j.jmb.2005.09.009 J. Mol. Biol. (2005) 353, 763–771 COMMUNICATION Androgen Receptor Binding Sites Identified by a GREF_GATA Model Katsuaki Masuda1, Thomas Werner2, Shilpi Maheshwari1 Matthias Frisch2, Soyon Oh1, Gyorgy Petrovics1, Klaus May2 Vasantha Srikantan1, Shiv Srivastava1 and Albert Dobi1* 1Center for Prostate Disease Changes in transcriptional regulation can be permissive for tumor Research, Department of progression by allowing for selective growth advantage of tumor cells. Surgery, Uniformed Services Tumor suppressors can effectively inhibit this process. The PMEPA1 gene, a University, Rockville, MD potent inhibitor of prostate cancer cell growth is an androgen-regulated 20852, USA gene. We addressed the question of whether or not androgen receptor can directly bind to specific PMEPA1 promoter upstream sequences. To test this 2Genomatix Software GmbH hypothesis we extended in silico prediction of androgen receptor binding D-80339 Munich, Germany sites by a modeling approach and verified the actual binding by in vivo chromatin immunoprecipitation assay. Promoter upstream sequences of highly androgen-inducible genes were examined from microarray data of prostate cancer cells for transcription factor binding sites (TFBSs). Results were analyzed to formulate a model for the description of specific androgen receptor binding site context in these sequences. In silico analysis and subsequent experimental verification of the selected sequences suggested that a model that combined a GREF and a GATA TFBS was sufficient for predicting a class of functional androgen receptor binding sites. The GREF matrix family represents androgen receptor, glucocorticoid receptor and progesterone receptor binding sites and the GATA matrix family represents GATA binding protein 1–6 binding sites.
    [Show full text]
  • Abx651433 Datasheet.Pdf
    Datasheet Version: 3.0.0 Revision date: 23 Apr 2021 Human Protein Kinase R (PKR) Protein (Active) Catalogue No.:abx651433 SDS-PAGE analysis of recombinant Human PKR. Western blot analysis of recombinant Human PKR, using PKR antibody (abx128520). Gene sequencing extract of recombinant Human PKR. Binding activity of PKR with CDK1. For Reference Only Human Protein Kinase R (PKR) Protein (Active) is a recombinant active Human protein expressed in E. coli. Target: Protein Kinase R (PKR) Origin: Human Tested Applications: WB, SDS-PAGE v1.0.0 Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951 1 of 3 Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413 Website: www.abbexa.com · Email: info@abbexa.com Datasheet Version: 3.0.0 Revision date: 23 Apr 2021 Host: E. coli Conjugation: Unconjugated Form: Lyophilized Purity: > 80% Reconstitution: Reconstitute to the original concentration in ddH2O. If further dilutions are required, dilute in 20 mM Tris, 150 mM NaCl, pH 8.0, to a concentration of 0.1-1.0 mg/ml. Do not vortex. Storage: Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles. UniProt Primary AC: P19525 (UniProt, ExPASy) KEGG: hsa:5610 String: 9606.ENSP00000233057 Molecular Weight: Calculated MW: 35.8 kDa Observed MW: 32 kDa Possible reasons why the actual band size differs from the predicted band size: 1. Splice variants. Alternative splicing may create different sized proteins from the same gene. 2. Relative charge. The composition of amino acids may affect the charge of the protein.
    [Show full text]
  • Muscle Wasting in Myotonic Dystrophies: a Model of Premature Aging
    REVIEW published: 09 July 2015 doi: 10.3389/fnagi.2015.00125 Muscle wasting in myotonic dystrophies: a model of premature aging Alba Judith Mateos-Aierdi 1,2, Maria Goicoechea 1,2, Ana Aiastui 2,3, Roberto Fernández-Torrón 1,2,4, Mikel Garcia-Puga 5, Ander Matheu 5 and Adolfo López de Munain 1,2,4,6* 1 Neuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain, 2 CIBERNED, Instituto Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain, 3 Cell Culture Platform, Biodonostia Health Research Institute, San Sebastián, Spain, 4 Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain, 5 Oncology Area, Biodonostia Health Research Institute, San Sebastián, Spain, 6 Department of Neuroscience, Universidad del País Vasco UPV-EHU, San Sebastián, Spain Myotonic dystrophy type 1 (DM1 or Steinert’s disease) and type 2 (DM2) are multisystem disorders of genetic origin. Progressive muscular weakness, atrophy and myotonia are the most prominent neuromuscular features of these diseases, while other clinical manifestations such as cardiomyopathy, insulin resistance and cataracts are also common. From a clinical perspective, most DM symptoms are interpreted as a result of an accelerated aging (cataracts, muscular weakness and atrophy, cognitive decline, metabolic dysfunction, etc.), including an increased Edited by: Jaime J. Carvajal, risk of developing tumors. From this point of view, DM1 could be described as Centro Andaluz de Biología del a progeroid syndrome since a notable age-dependent dysfunction of all systems Desarrollo, Spain occurs. The underlying molecular disorder in DM1 consists of the existence of Reviewed by: a pathological (CTG) triplet expansion in the 3’ untranslated region (UTR) of the John Charles McDermott, York University, Canada Dystrophia Myotonica Protein Kinase (DMPK) gene, whereas (CCTG)n repeats in Daniela Palacios, the first intron of the Cellular Nucleic acid Binding Protein/Zinc Finger Protein Fondazione Santa Lucia, Italy 9 (CNBP/ZNF9) gene cause DM2.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Supplemental Table 1: Genes That Show Altered Expression in Hepg2 Cells in the Presence of Exogenously Added Let-7
    Supplemental Table 1: Genes that show altered expression in HepG2 cells in the presence of exogenously added let-7 Gene Title Gene Symbol RefSeq Transcriptp- IDvalue(TREAp-TMENTvalue(Let7bS) - negativLog2 Reatio control1) (Let7b - negativp-value(Let7be control1) - negativLog2 Reatio control2) (Let7b - negative control2) aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-reductase) AKR1D1 NM_005989 3.28E-12 2.52E-12 -3.85007 3.59E-12 -3.73727 lin-28 homolog B (C. elegans) LIN28B NM_001004317 6.13E-15 8.29E-15 -3.29879 1.55E-15 -3.79656 high mobility group AT-hook 2 /// high mobility group AT-hook 2 HMGA2 NM_001015886 /// NM_0034833.74E-14 /// NM_0034844.29E-14 -3.06085 4.56E-14 -3.04538 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 NM_020760 1.27E-13 6.65E-13 -2.94724 4.47E-12 -2.50907 cell division cycle 25A CDC25A NM_001789 /// NM_2015672.01E-11 7.32E-11 -2.88831 1.99E-11 -3.22735 hypothetical protein FLJ21986 FLJ21986 NM_024913 1.05E-09 5.19E-10 -2.80277 1.18E-09 -2.61084 solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 NM_006931 1.59E-13 3.49E-13 -2.78111 1.84E-12 -2.41734 Transcribed locus --- --- 2.58E-13 1.08E-13 -2.59794 1.69E-13 -2.50248 Hypothetical protein LOC145786 LOC145786 --- 4.23E-12 1.07E-11 -2.58849 3.00E-12 -2.88135 Dicer1, Dcr-1 homolog (Drosophila) DICER1 NM_030621 /// NM_1774381.06E-08 4.37E-09 -2.5442 4.49E-09 -2.53796 mannose-binding lectin (protein C) 2, soluble (opsonic defect) MBL2 NM_000242 9.73E-10 1.48E-09 -2.53211 9.84E-10 -2.62363 cell
    [Show full text]
  • Genome-Wide Association Study of Multiplex Schizophrenia Pedigrees
    Article Genome-Wide Association Study of Multiplex Schizophrenia Pedigrees Douglas F. Levinson, M.D. Anthony O’Neill, M.D. in the primary European-ancestry analyses). Association was tested for single SNPs and Jianxin Shi, Ph.D. George N. Papadimitriou, M.D. genetic pathways. Polygenic scores based Kai Wang, Ph.D. Dimitris Dikeos, M.D. on family study results were used to predict case-control status in the Schizophrenia Sang Oh, M.Sc. Wolfgang Maier, M.D. Psychiatric GWAS Consortium (PGC) data set, and consistency of direction of effect Brien Riley, Ph.D. Bernard Lerer, M.D. with the family study was determined for Ann E. Pulver, Ph.D. Dominique Campion, M.D., top SNPs in the PGC GWAS analysis. Within- family segregation was examined for Dieter B. Wildenauer, Ph.D. Ph.D. schizophrenia-associated rare CNVs. Claudine Laurent, M.D., Ph.D. David Cohen, M.D., Ph.D. Results: No genome-wide significant asso- Maurice Jay, M.D. ciations were observed for single SNPs or for Bryan J. Mowry, M.D., pathways. PGC case and control subjects F.R.A.N.Z.C.P. Ayman Fanous, M.D. had significantly different genome-wide Pablo V. Gejman, M.D. Peter Eichhammer, M.D. polygenic scores (computed by weighting their genotypes by log-odds ratios from the 2 Michael J. Owen, Ph.D., Jeremy M. Silverman, Ph.D. family study) (best p=10 17, explaining F.R.C.Psych. 0.4% of the variance). Family study and Nadine Norton, Ph.D. PGC analyses had consistent directions for Kenneth S. Kendler, M.D.
    [Show full text]
  • The Dual Role of Micrornas in Colorectal Cancer Progression
    International Journal of Molecular Sciences Review The Dual Role of MicroRNAs in Colorectal Cancer Progression Lei Ding 1,2,†, Zhenwei Lan 1,2,†, Xianhui Xiong 1,2, Hongshun Ao 1,2, Yingting Feng 1,2, Huan Gu 1,2, Min Yu 1,2 and Qinghua Cui 1,2,* 1 Lab of Biochemistry & Molecular Biology, School of Life Sciences, Yunnan University, Kunming 650091, China; dingleiynu@ynu.edu.cn (L.D.); lanzhenweiL@163.com (Z.L.); xiongxianhui1995@163.com (X.X.); aohongshun@163.com (H.A.); fengyingting1994@163.com (Y.F.); albertwesker0112@163.com (H.G.); yumin@ynu.edu.cn (M.Y.) 2 Key Lab of Molecular Cancer Biology, Yunnan Education Department, Kunming 650091, China * Correspondence: cuiqinghua@ynu.edu.cn; Tel.: +86-871-65031412 † These authors contributed equally to this work. Received: 29 August 2018; Accepted: 13 September 2018; Published: 17 September 2018 Abstract: Colorectal cancer (CRC) is responsible for one of the major cancer incidence and mortality worldwide. It is well known that MicroRNAs (miRNAs) play vital roles in maintaining the cell development and other physiological processes, as well as, the aberrant expression of numerous miRNAs involved in CRC progression. MiRNAs are a class of small, endogenous, non-coding, single-stranded RNAs that bind to the 3’-untranslated region (30-UTR) complementary sequences of their target mRNA, resulting in mRNA degradation or inhibition of its translation as a post-transcriptional regulators. Moreover, miRNAs also can target the long non-coding RNA (lncRNA) to regulate the expression of its target genes involved in proliferation and metastasis of CRC. The functions of these dysregulated miRNAs appear to be context specific, with evidence of having a dual role in both oncogenes and tumor suppression depending on the cellular environment in which they are expressed.
    [Show full text]
  • Stroke Genetics and Genomics
    Faculdade de Medicina da Universidade de Lisboa Unidade Neurológica de Investigação Clínica PhD Thesis Stroke Genetics and Genomics Tiago Krug Coelho Host Institution: Instituto Gulbenkian de Ciência Supervisor at Instituto Gulbenkian de Ciência: Doctor Sofia Oliveira Supervisor at Faculdade de Medicina da Universidade de Lisboa: Professor José Ferro PhD in Biomedical Sciences Specialization in Neurosciences 2010 Stroke Genetics and Genomics A ciência tem, de facto, um único objectivo: a verdade. Não esgota perfeitamente a sua tarefa se não descobre a causa do todo. Chiara Lubich i Stroke Genetics and Genomics ii Stroke Genetics and Genomics A impressão desta dissertação foi aprovada pela Comissão Coordenadora do Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 28 de Setembro de 2010. iii Stroke Genetics and Genomics iv Stroke Genetics and Genomics As opiniões expressas são da exclusiva responsabilidade do seu autor. v Stroke Genetics and Genomics vi Stroke Genetics and Genomics Abstract ABSTRACT This project presents a comprehensive approach to the identification of new genes that influence the risk for developing stroke. Stroke is the leading cause of death in Portugal and the third leading cause of death in the developed world. It is even more disabling than lethal, and the persistent neurological impairment and physical disability caused by stroke have a very high socioeconomic cost. Moreover, the number of affected individuals is expected to increase with the current aging of the population. Stroke is a “brain attack” cutting off vital blood and oxygen to the brain cells and it is a complex disease resulting from environmental and genetic factors.
    [Show full text]